Consensus-based recommendations for the management of juvenile localised scleroderma

Dougados "EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees" Ann Rheum Dis (2004) 10.1136/ard.2004.023697

[4]

Collaboration T C Cochrane handbook for systematic reviews of interventions (2013)

[5]

Zhang "EULAR evidence based recommendations for gout. Part II: Management. Report of a task Force of the EULAR standing Committee for international clinical studies including therapeutics (ESCISIT)" Ann Rheum Dis (2006) 10.1136/ard.2006.055269

[6]

Herrick "Incidence of childhood linear scleroderma and systemic sclerosis in the UK and ireland" Arthritis Care Res (2010) 10.1002/acr.20070

[7]

Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study

F. Zulian, B. H. Athreya, R. Laxer et al.

Rheumatology 2006 10.1093/rheumatology/kei251

[8]

Zulian "Congenital localized scleroderma" J Pediatr (2006) 10.1016/j.jpeds.2006.04.052

[9]

Martini "Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology centre and literature review" Autoimmun Rev (2018) 10.1016/j.autrev.2018.02.004

[10]

Arkachaisri "The localized scleroderma skin severity Index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures" J Rheumatol (2009) 10.3899/jrheum.081284

[11]

Arkachaisri "Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study" Rheumatology (2010) 10.1093/rheumatology/kep361

[12]

Kelsey "The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population" J Am Acad Dermatol (2013) 10.1016/j.jaad.2013.02.007

[13]

Martini "Juvenile-onset localized scleroderma activity detection by infrared thermography" Rheumatology (2002) 10.1093/rheumatology/41.10.1178

[14]

Li "Ultrasonography is a sensitive tool for monitoring localized scleroderma" Rheumatology (2007) 10.1093/rheumatology/kem120

[15]

Li "Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma" Arthritis Care Res (2011) 10.1002/acr.20407

[16]

Zulian "Localized scleroderma in childhood is not just a skin disease" Arthritis Rheum (2005) 10.1002/art.21264

[17]

Schanz "Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach" AJR Am J Roentgenol (2013) 10.2214/ajr.12.9335

[18]

Schanz "Localized scleroderma: Mr findings and clinical features" Radiology (2011) 10.1148/radiol.11102136

[19]

Chiu "A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings" Pediatr Dermatol (2012) 10.1111/pde.12001

[20]

Blaszczyk "Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre" J Rheumatol (2003)

[21]

Flores-Alvarado "Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship?" J Rheumatol (2003)

[22]

Zannin "Ocular involvement in children with localised scleroderma: a multi-centre study" Br J Ophthalmol (2007) 10.1136/bjo.2007.116038

[23]

Trainito "Odontostomatologic involvement in juvenile localised scleroderma of the face" J Paediatr Child Health (2012) 10.1111/j.1440-1754.2012.02435.x

[24]

Zulian "Scleroderma in children" Best Pract Res Clin Rheumatol (2017) 10.1016/j.berh.2018.02.004

[25]

Uziel "Methotrexate and corticosteroid therapy for pediatric localized scleroderma" J Pediatr (2000) 10.1016/s0022-3476(00)90056-8

[26]

Weibel "Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children" Br J Dermatol (2006) 10.1111/j.1365-2133.2006.07497.x

[27]

Joly "Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients" Arch Dermatol (1994) 10.1001/archderm.1994.01690050133027

[28]

Zulian "Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial" Arthritis Rheum (2011) 10.1002/art.30264

[29]

Zulian "A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)" J Am Acad Dermatol (2012) 10.1016/j.jaad.2012.03.036

[30]

Torok "Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study" J Rheumatol (2012) 10.3899/jrheum.110210

[31]

Martini "Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil" Rheumatology (2009) 10.1093/rheumatology/kep244

[32]

Pope "Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study" Dermatology (2011) 10.1159/000335560

[33]

Dytoc "First case series on the use of imiquimod for morphoea" Br J Dermatol (2005) 10.1111/j.1365-2133.2005.06776.x

[34]

Wooten "Imiquimod" South Med J (2005) 10.1097/01.smj.0000170854.47749.19

[35]

Spaner "Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod" Leuk Lymphoma (2005) 10.1080/10428190500054426

[36]

Kreuter "A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma" J Am Acad Dermatol (2006) 10.1016/j.jaad.2005.11.1063

[37]

Su "Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma" Int J Dermatol (2011) 10.1111/j.1365-4632.2010.04843.x

[38]

de Rie "Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method" Dermatology (2003) 10.1159/000073093

[39]

Staberg "The carcinogenic effect of UVA irradiation" J Invest Dermatol (1983) 10.1111/1523-1747.ep12522855

[40]

Li "Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists" J Rheumatol (2010) 10.3899/jrheum.090708

[41]

Martini "Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?" Clin Exp Rheumatol (2017)

[42]

Foeldvari "Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients" J Scleroderma Relat Disord (2017) 10.5301/jsrd.5000259

[43]

Lythgoe "Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma" Rheumatology (2018) 10.1093/rheumatology/kex382

[44]

Enders "Consensus-based recommendations for the management of juvenile dermatomyositis" Ann Rheum Dis (2017) 10.1136/annrheumdis-2016-209247

Cited By

99

Neuroimaging and Clinical Features of Parry-Romberg Syndrome and Linear Morphea En-coup-de-sabre in a Large Case Series

Vineet Vijay Gorolay, Ryan Fisicaro · 2025

Academic Radiology

Metrics

99

Citations

44

References

Details

Published: Aug 01, 2019
Vol/Issue: 78(8)
Pages: 1019-1024
License: View

Authors

Sheila Knupp Feitosa de Oliveira

C

Clarissa A Pilkington

Claudia Saad Magalhães

Funding

This project was supported by a grant from European Agency for Health and Consumers Award: Grant number 20111202

Cite This Article

Francesco Zulian, Roberta Culpo, Francesca Sperotto, et al. (2019). Consensus-based recommendations for the management of juvenile localised scleroderma. Annals of the Rheumatic Diseases, 78(8), 1019-1024. https://doi.org/10.1136/annrheumdis-2018-214697

Consensus-based recommendations for the management of juvenile localised scleroderma

You May Also Like